Cost‐Effectiveness of Dimethyl Fumarate Versus Teriflunomide in Patients With Relapsing‐Remitting Multiple Sclerosis (RRMS) in Iran

Documenti analoghi

• Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS
  di: F. Shawket, et al.
  Pubblicazione: (2026)
• Cytomegalovirus Infection in a Multiple Sclerosis Patient on Dimethyl Fumarate
  di: Nicolai Larsen
  Pubblicazione: (2025)
• Sleep Disturbance and Related Factors in the Patients with Relapsing‐Remitting Multiple Sclerosis
  di: Izabela Sempik, et al.
  Pubblicazione: (2024)
• Health Information Avoidance and eHealth Literacy in Patients With Multiple Sclerosis: A Cross‐Sectional Correlational Study
  di: Leila Mobasher, et al.
  Pubblicazione: (2025)
• MR Susceptibility Separation for Quantifying Lesion Paramagnetic and Diamagnetic Evolution in Relapsing–Remitting Multiple Sclerosis
  di: Ziyan Zhu, et al.
  Pubblicazione: (2024)